Hoppa till innehållet

Karl Keegan

Biotechnology Valuation

  • Vikt 0,57 kg

896 krhos Bokus · exkl. frakt

273 kr skillnad mellan billigaste och dyraste butik i lager

896 kr1 169 kr

Dubbelkollat idag

Jämför 2 butiker

Priser från butikernas flöden kan ha ändrats: det är priset hos butiken som gäller, så kontrollera det innan du handlar.

Prishistorik

Köp nu eller vänta?

Just nu kostar produkten 896 kr — 28 kr över det lägsta vi sett på 1 månad.

Pris idag

896 kr

900850800
snitt 884 kr15 sep.Idag
15 september 2026
868 kr
Lägst hos Bokus
Lägst
868 kr
Snitt
884 kr
Högst
896 kr
Lägsta pris per dag
2026-09-15868 kr · Lägst hos Bokus
2026-10-05896 kr · Lägst hos Bokus

Om produkten

Biotechnology Valuation

Läs mer

The first book to provide a simple and practical means of valuing biotech companiesThe book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dipsIt examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the USLooks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate themPraise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan's book, punctuated with his personal experience and opinions, is a good place to start."-Chris Blackwell, Chief Executive, Vectura Group plc"A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians."-Steve Winokur, Managing Director, CanaccordAdams"A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value."-Dr L.M. Allan, Director, Bioscience Enterprise Programme, University of Cambridge"A fabulous approach to a difficult topic."-Deirdre Y. Gillespie, MD, President & CEO, La Jolla Pharmaceutical Company

Specifikationer

Fakta

Vikt
0,57 kg
GTIN
09780470511787

Uppgifter från tillverkare och butiker.